Sartorius Stedim Biotech Shares Up 2.44%, Targeting Key Technical Threshold at €184
The French bioproduction equipment specialist continues its recovery midday. The stock is regaining strength in a sharply rising SBF 120, approaching a technical threshold closely watched for several sessions. The session is also marked by a recent broker update.
15% Rebound Over a Month Brings Sartorius Stedim Biotech Closer to its €184 Resistance
Sartorius Stedim Biotech is up 2.44% at €180.80, in an SBF 120 that has risen by 0.67%. The stock is nearing its resistance at €184.00, the last barrier before a return to the MM200 at €185.31. The price is now above the MM20 (€167.94) and MM50 (€168.76), with a gap of about 7% on each, but remains slightly below the MM200 (gap of -2.43%). The RSI at 60 indicates a bullish momentum without excess, consistent with a MACD that has moved above its signal line. The one-month gain reaches 15.38%, while the €185 threshold mentioned at the end of May remains within reach. Over a year, the stock still shows a decline of 4.64%.
HSBC Adjusts Its Target to €230 While Maintaining a Buy Recommendation
HSBC lowered its price target from €233 to €230 on June 3, while reaffirming its buy recommendation. The target still offers a potential of about 27% relative to the current price. Based on the expected earnings per share, the stock is priced at approximately 35.8 times the earnings for the current fiscal year, according to the consensus of analysts surveyed. The stock has risen over the month, extending the recovery that began in mid-May after a dip below its moving averages. The €184 resistance remains the next level to watch to extend or halt the ongoing movement.
